Cresca Capital is a boutique advisory firm focused exclusively on life sciences — with a focus on neuro/CNS, pain, women's health, and longevity. We advise on M&A, fundraising, and strategic partnerships from strategy through close.
Therapeutic Focus
Deep domain expertise at the intersection of life sciences and high-stakes dealmaking.
Cresca Capital was built for biotech founders, investors, and strategics who need a partner that understands both the science and the market dynamics driving value creation in this sector.
Our focus spans the full lifecycle of life sciences companies: from early-stage fundraising and Series A strategy through strategic partnership development, acquisition targeting, and full deal execution.
Partners with MD/PhD and scientific backgrounds who understand your science — not just your financials.
Direct relationships with life sciences VCs, strategic pharma partners, institutional investors, and family offices active in biotech.
Licensed representatives with hands-on experience in PIPE, Follow-On, Private Placement, IPO processes, and M&A execution.
We roll up our sleeves. From diligence to term sheets to closing — we manage the process so you stay focused on your core priorities.
Project-based, ongoing retainer structures, or success fees tailored to your deal timeline, team capacity, and stage of growth.
Services
Institutional-grade M&A and fundraising support — without the bulge-bracket overhead.
Full deal lifecycle support — target identification, diligence, financial modeling, valuation, deal structuring, and closing execution for biotech and life sciences transactions.
From Series A through late-stage: investor narrative development, pitch materials, investor targeting, term sheet guidance, and support through close.
PIPE, Follow-On, Private Placement, and IPO advisory. Strategic positioning, competitive differentiation, and investor communication for biotech companies accessing public and private capital.
Reshape your external narrative and build a comprehensive IR function. From equity story development and analyst onboarding to Investor Days, earnings processes, and Disclosure Protocols.
Identify, approach, and close strategic partnerships with pharma, diagnostics, and health system partners. We build your pipeline, lead outreach, and participate in negotiations end-to-end.
Financial models, milestone-based valuations, revenue projections, recapitalization structuring, and board materials tailored to biotech-specific metrics.
Our Partners
Founder & Partner
Heloise advises on M&A and fundraising as a Registered Representative with Cresca Capital, a life sciences-focused advisory firm (neuro/CNS, pain, women's health, and longevity), and as a Partner at Luminarc Labs, where she works with investors and startups on high-impact projects.
Her hands-on deal experience spans the full lifecycle — from sourcing and diligence through execution and closing. She has managed the acquisition of a Stanford IP-backed biotech asset, executed the launch of a biotech-focused hedge fund, and advised several biotech startups on strategic projects.
Prior to these roles, she sourced and diligenced acquisition and investment opportunities at Saltwater Capital (family office of Ryan Graves, Uber's first CEO), Thrasio (Series D unicorn startup), and Secocha Ventures (early-stage VC). She began her career as a Summer Analyst at Bank of America and Deutsche Bank.
Principal Advisor
Dr. Meissner is a physician–scientist, experienced biotech executive, and investment banker with broad expertise across immunology, oncology, infectious diseases, and metabolic disorders. She brings a rare combination of deep scientific expertise, capital markets knowledge, broad investor network, and a strong track record in corporate strategy and capital raising.
Previously, she served as Vice President Strategy & Global Head of Investor Relations at BioNTech (BNTX), where she led the transformation of the company's external narrative — repositioning it from a COVID-19 vaccine biotech to a global oncology leader. She reshaped the IR function from the ground up, built the earnings and financial forecasting processes, redesigned the Disclosure Protocol alongside Legal, and participated in Business Development transactions including the licensing of a PD-L1/VEGF bispecific antibody and support of the Biotheus acquisition. She joined in early 2023 when BioNTech's market cap was approximately $30 billion.
Prior to BioNTech, Victoria worked at Jefferies advising biotech clients on capital raising (PIPE, Follow-On, Private Placement, IPO) and M&A, and at Westwicke, where she first supported BioNTech through multiple private financing rounds ahead of its IPO. She is a founding member of the Buysiders Club and serves on the Executive Leadership Committee of the American Heart Association's Heart of the Hamptons chapter.
Contact
Whether you're a biotech founder preparing for your next round, an investor seeking deal flow or diligence support, or a strategic exploring acquisition opportunities — let's talk.
Start a ConversationCresca Capital · Life Sciences M&A Advisory
Securities are offered through Finalis Securities LLC Member FINRA / SIPC. Cresca Capital is not a registered broker-dealer, and Finalis Securities LLC and Cresca Capital are separate, unaffiliated entities. Finalis Securities LLC, Office of Supervisory Jurisdiction is located at 450 Lexington Ave, New York, NY 10017, 800-962-0418.
crescacap.com (the “Cresca Capital Website”) is a website operated by Cresca Capital. This website is for informational purposes only, is not an offer, solicitation, recommendation, or commitment for any transaction or to buy or sell any security or other financial product, and is not intended as investment advice or as a confirmation of any transaction. Products and services on this website may not be available for residents of certain jurisdictions. Please consult with a Finalis Securities’ registered representative regarding the product or service in question for further information. Investments involve risk and are not guaranteed to appreciate. Any market price, indicative value, estimate, view, opinion, data, or other information herein is not warranted as to completeness or accuracy, is subject to change without notice, and Cresca Capital along with Finalis Securities LLC accepts no liability for its use or to update it or keep it current.
Investing in private placements involves a high degree of risk. These investments may be illiquid, speculative, and subject to substantial restrictions on transferability. Investors may lose all or part of their investment and should only invest capital they can afford to lose. Prospective investors should conduct their own due diligence and consult with their legal, tax, and financial advisors prior to making any investment decision. For your reference, Finalis’ Form CRS describes the services that we provide, how we are compensated, and other important information about Finalis Securities LLC.